INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
申请人:Kondo Tatsuhiro
公开号:US20120122931A1
公开(公告)日:2012-05-17
A compound represented by the general formula (I) of the present invention, which has an EP
1
receptor antagonism:
[wherein A represents a benzene ring or the like; Y represents a C
1-6
alkylene group or the like; R
N
represents a hydrogen atom or a C
1-6
alkyl group; R
1
represents a hydrogen atom, a C
1-6
alkyl group or the like; R
2
represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like; R
3
represents a halogen atom, a C
1-6
alkoxy group or the like; R
4
represents a hydrogen atom or the like; and R
5
represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
agriculture, but the presence of a steroid skeleton hampers the field application of BL in agriculture because of its high synthetic cost. We discovered NSBR1 as the first nonsteroidal BL-like compound using in silico technology. Searching for more potent BL-like compounds, we modified the structure of NSBR1 with respect to 2 benzene rings and the piperazine ring. The activity of synthesized compounds